Alios BioPharma is a privately held, clinical stage, biotechnology company in South San Francisco, California that is developing novel medicines aimed at the treatment of viral diseases. In collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX), Alios is developing VX-135 (formerly known as ALS-2200), a uridine nucleotide analog, for the treatment of chronic hepatitis C. VX-135 began Phase 2 clinical develpment with all-oral regimens in early 2013 and is expected to be in pivotal development beginning in 2014. Alios has developed a novel proprietary nucleoside/tide library to identify therapeutics for the treatment of several viral infections beyond HCV, including RSV, rhinovirus, norovirus, influenza and other emerging viral diseases. Additionally, Alios is developing non-nucleoside/tide small molecule therapeutics that will complement its nucleoside/tide portfolio. The overall goal for the Alios therapeutic platform is to maximize patient benefits in areas of high unmet medical need through optimization of potency, safety and tolerability.
Please check back in the future for job listings.